TherapeuticsMD Q2 2026 net income $164K, revenue $869K; explores strategic alternatives

TherapeuticsMD, Inc.

Net income from continuing operations $164K vs $545K in Q2 2025; license revenue $869K vs $952K.
Total operating expenses $1.7M, up 2.3% YoY on higher G&A and patent write-off.
Cash and cash equivalents $9.2M as of June 30, 2026.
Company continues evaluating strategic alternatives including merger, sale, or other transactions; no timetable set.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.